RedHill Biopharma : Exercise of Existing Warrants Resulting in $4 Million Proceeds to the Company - Form 6-K -December 06, 2023 at 07:05 am EST
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C....
Source: marketscreener.com
Page 6 - Expanded Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Expanded Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Expanded Access Program Today - Breaking & Trending Today
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new non-dilutive external funding, additional to the previously announced U.S. Government funding, which now covers the entirety of the RHB-107 (upamostat) arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment. This additional funding amounts to approximately $4.8M directed towards evaluation of RHB-107 in the PROTECT study.
Source: yahoo.com
Brainstorm Cell Therapeutics' (NASDAQ: BCLI) Post-Setback Resurgence: Unpacking FDA Impact & Market Expectations
Brainstorm Cell Therapeutics (NASDAQ: BCLI) continues to gain momentum with a surge of over 125% since its low on October 31st, 2023. Following an unfavourable FDA decision on its ALS treatment, the stock hit an all-time low of $0.13 per share. Nethertheless, the stock experienced a significant rebound today, November 30th, 2023, rising by 26%, […]
Source: microcapdaily.com
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nine company-sponsored presentations, including five late-breaking abstracts, will...
Source: prnewswire.com
